Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reproductive Health
Published in: Reproductive Health 1/2018

Open Access 01-12-2018 | Research

Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study

Authors: Adriane M. Delicio, Giuliane J. Lajos, Eliana Amaral, Fernanda Cavichiolli, Marina Polydoro, Helaine Milanez

Published in: Reproductive Health | Issue 1/2018

Login to get access

Abstract

Background

Antiretroviral therapy (ART) in pregnancy was associated with a drastic reduction in HIV mother-to-child transmission (MTCT), although it was associated with neonatal adverse effects. The aim of this study was to evaluate the neonatal effects to maternal ART.

Methods

This study was a cohort of newborns from HIV pregnant women followed at the CAISM/UNICAMP Obstetric Clinic from 2000 to 2015. The following adverse effects were evaluated: anemia, thrombocytopenia, liver function tests abnormalities, preterm birth, low birth weight and congenital malformation. Data collected from patients’ files was added to a specific database. Descriptive analysis was shown in terms of absolute (n) and relative (%) frequencies and mean, median and standard deviation calculations. The association between variables was tested through Chi-square or Fisher exact test (n < 5) and relative risk (RR) with its respective p values for the categorical ones and t-Student (parametric data) or Mann-Whitney (non-parametric data) for the quantitative ones. The significant level used was 0.05. A multivariate Cox Logistic Regression was done. Statistical analysis was performed using SAS version 9.4.

Results

Data from 787 newborns was analyzed. MTCT rate was 2.3%, with 0.8% in the last 5 years. Observed neonatal adverse effects were: liver function tests abnormalities (36%), anemia (25.7%), low birth weight (22.5%), preterm birth (21.7%), children small for gestational age (SGA) (18%), birth defects (10%) and thrombocytopenia (3.6%). In the multivariate analysis, peripartum CD4 higher than 200 cells/mm3 was protective for low birth weight and preterm birth, and C-section was associated with low birth weight, but not with preterm birth. Neonatal anemia was associated with preterm birth and exposure to maternal AZT. Liver function tests abnormalities were associated with detectable peripartum maternal viral load and exposure to nevirapine. No association was found between different ART regimens or timing of exposure with preterm birth, low birth weight or congenital malformation.

Conclusion

Highly active antiretroviral treatment in pregnant women and viral load control were the main factors associated with MTCT reduction. Antiretroviral use is associated with a high frequency but mainly low severity adverse effects in newborns.
Literature
1.
WHO. Global AIDS update. Ending AIDS towards the 90–90-90 targets. Geneva: UNAIDS; 2017.
2.
The Working Group on Mother-To-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(5):506–10.CrossRef
3.
Tess BH, Rodrigues LC, Newell ML, Dunn DT, Lago TDG. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in São Paulo state. Brazil AIDS. 1998;12:513–20.CrossRefPubMed
4.
Baggaley R, Doherty M, Ball A, Ford N, Gottfried HG. Department of HIV/AIDS, World Health Organization, Geneva, Switzerland. The strategic use of Antiretrovirals to prevent HIV infection: a converging agenda. Clin Infect Dis. 2015;60(Suppl 3):159–60.CrossRef
5.
French CE, Thorne C, Byrne L, Cortina-Borja M, Tookey PA. Presentation for care and antenatal management of HIV in the UK, 2009-2014. HIV Med. 2017;18(Suppl 3):161–70.CrossRefPubMed
6.
Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan M, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–80.CrossRefPubMed
7.
WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.
8.
Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. The INSIGHT START study group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.CrossRefPubMed
9.
McCormack SA, Best BM. Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet. 2014;53(Suppl 11):989–1004.CrossRefPubMedPubMedCentral
10.
Himes SK, Tassiopoulos K, Yogev R, Huestis MA. Pediatric HIV/AIDS Cohort Study (PHACS).Antiretroviral drugs in meconium: detection for different gestational periods of exposure. J Pediatr. 2015;167(Suppl 2):305–11.CrossRefPubMedPubMedCentral
11.
Senise JF, Castelo A, Martínez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev. 2011;13(Suppl 4):198–213.PubMed
12.
Kourtis AP, Wiener J, Kayira D, Chasela C, Ellington SR, Hyde L, et al. Health outcomes of HIV-exposed uninfected African infants. AIDS. 2013;27(Suppl 5):749–59.CrossRefPubMedPubMedCentral
13.
Newell ML, Bunders MJ. Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. Curr Opin HIV AIDS. 2013;8(Suppl 5):504–10.CrossRefPubMed
14.
Williams PL, Hazra R, Van Dyke RB, Yildirim C, Crain MJ, Seage GR 3rd, Civitello L, Ellis A, Butler L, Rich K, Pediatric HIV/AIDS Cohort Study. Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design. AIDS. 2016;30(Suppl 1):133–44.PubMedPubMedCentral
15.
Lubchenco LO, Hansman C, Dressler M, Boyde E. Intrauterine growth as estimate from liveborn birth-weight data at 24 to 42 weeks of gestation. Pediatrics. 1963;32:793–800.PubMed
16.
Baeth SV. Hepatic function and physiologyin the newborn. Semin Neonatol. 2003;8:337–46.CrossRef
17.
Dos Reis HL, Araujo Kda S, Ribeiro LP, Da Rocha DR, Rosato DP, Passos MR, et al. Preterm birth and fetal growth restriction in HIV-infected Brazilian pregnant women. Rev Inst Med Trop Sao Paulo. 2015;57(Suppl 2):111–20.CrossRefPubMedPubMedCentral
18.
Passini R Jr, Cecatti JG, Lajos GJ, Tedesco RP, Nomura ML, Dias TZ, et al. Brazilian multicentre study on preterm birth study group. Brazilian multicentre study on preterm birth (EMIP): prevalence and factors associated with spontaneous preterm birth. PLoS One. 2014;9(Suppl 10):e109069.CrossRefPubMedPubMedCentral
19.
Santini-Oliveira M, Friedman RK, Veloso VG, Cunha CB, Pilotto JH, Marins LM, et al. Incidence of antiretroviral adverse drug reactions in pregnant women in two referral centers for HIV prevention of mother-to-child-transmission care and research in Rio de Janeiro, Brazil. Braz J Infect Dis. 2014;18(Suppl 4):372–8.CrossRefPubMed
20.
Kourtis AP, Fowler MG. Antiretroviral use during pregnancy and risk of preterm delivery: more questions than answers. J Infect Dis. 2011;204(Suppl 4):493–4.CrossRefPubMed
21.
Slyker JA, Patterson J, Ambler G, Richardson BA, Maleche-Obimbo E, Bosire R, et al. Correlates and outcomes of preterm birth, low birth weight, and small for gestational age in HIV-exposed uninfected infants. BMC Pregnancy Childbirth. 2014;14:7.CrossRefPubMedPubMedCentral
22.
Xiao PL, Zhou YB, Chen Y, Yang MX, Song XX, Shi Y, et al. Association between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies. BMC Pregnancy Childbirth. 2015;15:246.CrossRefPubMedPubMedCentral
23.
Kennedy CE, Yeh PT, Pandey S, Betran AP, Narasimhan M. Elective caesarean section for women living with HIV: a systematic review of risks and benefits. AIDS. 2017;31:1579–91.CrossRefPubMedPubMedCentral
24.
Kreitchmann R, Li SX, Melo VH, Fernandes Coelho D, Watts DH, Joao E, et al. Predictors of adverse pregnancy outcomes in women infected with HIV in Latin America and the Caribbean: a cohort study. BJOG. 2014;121(Suppl 12):1501–8.CrossRefPubMedPubMedCentral
25.
Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: a cohort study. J Infect Dis. 2016;213(Suppl 7):1057–64.CrossRefPubMed
26.
Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(Suppl 11):1695–705.CrossRefPubMedPubMedCentral
27.
28.
Kourtis AP, Schimidt CH, Jamieson DJ, Lau J. Use o f antirretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21:607–15.CrossRefPubMed
29.
Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(Suppl 18):1726–37.CrossRefPubMedPubMedCentral
30.
Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry. BJOG. 2016;123(Suppl 6):910–6.CrossRefPubMed
31.
Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, Tuomala RE, P1025 team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Prenatal protease inhibitor use and risk of preterm birth among HIV infected women initiating antiretroviraldrugs during pregnancy. J Infect Dis. 2010;201(Suppl 7):1035–44.CrossRefPubMedPubMedCentral
32.
Papp E, Mohammadi H, Loutfy MR, Yudin MH, Murphy KE, Walmsley SL, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggestin a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2015;211(Suppl 1):10–8.CrossRefPubMed
33.
Bengtson AM, Chibwesha CJ, Westreich D, Mubiana-Mbewe M, Vwalika B, Miller WC, et al. Duration of cART before delivery and low infant birthweight among HIV-infected women in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2016;71(Suppl 5):563–9.CrossRefPubMedPubMedCentral
34.
Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S, et al. Reassuring birth outcomes with Tenofovir/Emtricitabine/Efavirenz used for prevention of mother-to-child transmission of HIV in Botswana. J Acquir Immune Defic Syndr. 2016;71(Suppl 4):428–36.CrossRefPubMedPubMedCentral
35.
Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, et al. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67(Suppl 2):128–35.CrossRefPubMedPubMedCentral
36.
Obumneme-Anyim I, Ibeziako N, Emodi I, Ikefuna A, Oguonu T. Hematological indices at birth of infants of HIV-positive mothers participating in a prevention of mother-to-child transmission program. J Trop Pediatr. 2016;62(Suppl 1):3–9.CrossRefPubMed
37.
Feiterna-Sperling C, Weizsaecker K, BüHrer C, Casteleyn S, Loui A, Schmitz T, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1– exposed uninfected newborn infants. J Acquir Immune Defic Syndr. 2007;45:43–51.CrossRefPubMed
38.
Rovira N, Noguera-Julian A, Rives S, Berrueco R, Lahoz R, Fortuny C. Influence of new antiretrovirals on hematological toxicity in HIV-exposed uninfected infants. Eur J Pediatr. 2016;175(Suppl 7):1013–7.CrossRefPubMed
39.
Smith C, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, et al. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. PLoS One. 2015;10(Suppl 5):e0127062.CrossRefPubMedPubMedCentral
40.
41.
El Beitune P, Duarte G, Campbell O, Quintana SM, Rodrigues LC. Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in HIV-exposed, uninfected newborn infants. Braz J Infect Dis. 2007;11(Suppl 3):314–7.CrossRefPubMed
42.
Minniear TD, Zeh C, Polle N, Masaba R, Peters PJ, Oyaro B, et al. Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J. 2012;31(Suppl 11):1155–7.CrossRefPubMed
43.
Iveli P, Noguera-Julian A, Soler-Palacín P, Martín-Nalda A, Rovira-Girabal N, Fortuny-Guasch C, et al. Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy. Enferm Infecc Microbiol Clin. 2016;34(Suppl 1):39–44. Spanish.CrossRefPubMed
Metadata
Title
Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study
Authors
Adriane M. Delicio
Giuliane J. Lajos
Eliana Amaral
Fernanda Cavichiolli
Marina Polydoro
Helaine Milanez
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Reproductive Health / Issue 1/2018
Electronic ISSN: 1742-4755
DOI
https://doi.org/10.1186/s12978-018-0513-8

Other articles of this Issue 1/2018

Reproductive Health 1/2018 Go to the issue

Review

Effectiveness of respectful care policies for women using routine intrapartum services: a systematic review

Research

Partner influences on young women’s risky drug and sexual behavior

Research

Experiences of antenatal care among pregnant adolescents at Kanyama and Matero clinics in Lusaka district, Zambia

Research

Quality of IVF status registration in the Estonian Medical Birth Registry: a national record linkage study

Study protocol

The global maternal sepsis study and awareness campaign (GLOSS): study protocol

Research

Adolescents’ perceptions and experiences of pregnancy in refugee and migrant communities on the Thailand-Myanmar border: a qualitative study